In addition to the abnormal expression and activation of EZH2 in renal tumors, its expression levels and activity were also increased in acute kidney injury (AKI; Zhou et al., 2018b), renal fibrosis (Zhou et al., 2016), diabetic nephropathy (DN; Jia et al., 2019b), lupus nephritis (LN; Rohraff et al., 2019), hyperuricemic nephropathy (Shi et al., 2019), and transplanted and aging kidneys (Li et al., 2016; Han and Sun, 2020). Here, EZH2 is linked to liver dysplastic nodule.